GLSI:NASDAQGreenwich LifeSciences, Inc. Analysis
Data as of 2026-05-19 - not real-time
$26.88
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Greenwich LifeSciences (GLSI) is trading at $26.88, comfortably above its 20‑day ($23.97) and 50‑day ($24.84) moving averages and the 200‑day SMA ($17.76), indicating short‑term price strength. The RSI sits at 59 and the MACD histogram is positive, reinforcing a modest bullish bias, while volume is on an upward trend.
However, the company remains a pre‑revenue biotech with zero revenue, negative earnings, a negative cash flow profile and an astronomically high price‑to‑book multiple of 170, suggesting the stock is fundamentally overvalued. Recent news highlights a Nasdaq compliance notice for a late 10‑K filing, adding regulatory pressure, alongside an ATM financing program and continued Phase III trial activity, which together shape a mixed outlook of short‑term risk and longer‑term upside potential.
However, the company remains a pre‑revenue biotech with zero revenue, negative earnings, a negative cash flow profile and an astronomically high price‑to‑book multiple of 170, suggesting the stock is fundamentally overvalued. Recent news highlights a Nasdaq compliance notice for a late 10‑K filing, adding regulatory pressure, alongside an ATM financing program and continued Phase III trial activity, which together shape a mixed outlook of short‑term risk and longer‑term upside potential.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Nasdaq compliance notice creates near‑term uncertainty
- Technical support level at $21.25 and bullish MACD
- Increasing volume indicating market interest
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- Progress of Phase III FLAMINGO‑01 trial
- Access to capital via ATM financing
- Technical momentum with price above key moving averages
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential high payoff if immunotherapy succeeds
- Continued cash burn and lack of revenue
- Elevated valuation relative to fundamentals
Key Metrics & Analysis
Financial Health
P/E Ratio-32.8
ROE-543.43%
ROA-254.19%
P/B Ratio170.1
Op. Cash Flow$-8591002
Free Cash Flow$-1357228
Industry P/E26.9
Technical Analysis
TrendNeutral
RSI59.1
Support$21.25
Resistance$29.10
MA 20$23.97
MA 50$24.84
MA 200$17.76
MACDBullish
VolumeIncreasing
Fear & Greed Index89.61
Valuation
Target Price$47.50
Upside/Downside76.71%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.97
Volatility82.28%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.